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A pharmacokinetic–pharmacodynamic study was carried out to investigate the feasibility and potential importance of therapeutic
monitoring following high-dose carboplatin treatment in children. High-dose carboplatin was administered over 3 or 5 days, with the
initial dose based on renal function, to achieve target area under the plasma concentration–time curve (AUC) values of 21 or
20mgml
 1.min, respectively. Dose adjustment was carried out based on observed individual daily AUC values, to obtain the defined
target exposures. Platinum–DNA adduct levels were determined in peripheral blood leucocytes and toxicity data were obtained.
Twenty-eight children were studied. Based on observed AUC values, carboplatin dose adjustment was performed in 75% (21 out of
28) patients. Therapeutic monitoring resulted in the achievement of carboplatin exposures within 80–126% of target AUC values, as
compared to estimated exposures of 65–213% of target values without dose adjustment. The carboplatin AUC predicted with no
dose modification was positively correlated with pretreatment glomerular filtration rate (GFR) values. Higher GFR values were
observed in those patients who would have experienced AUC values 425% above the target AUC than those patients attaining
AUC values 425% below the target AUC, following renal function-based dosing. Platinum–DNA adduct levels correlated with
observed AUC values on day 1 of carboplatin and increased over a 5-day course of treatment. Real-time monitoring of carboplatin
pharmacokinetics with adaptive dosing is both feasible and necessary for the attainment of consistent AUC values in children
receiving high-dose carboplatin treatment. Pharmacodynamic data suggest a strong correlation between carboplatin pharmacoki-
netics and the drug–target interaction.
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Carboplatin is a second-generation platinum compound com-
monly used in paediatric oncology and currently plays a key role in
the treatment of many tumours, including neuroblastoma,
rhabdomyosarcoma, brain tumours and germ cell tumours
(Gaynon, 1994). It is estimated that approximately one-third of
children with solid tumours will receive carboplatin as part of
multimodal chemotherapy at some point during their treatment.
As the pharmacokinetics of carboplatin are largely determined by
the renal function of the patient being treated, dosing formulae
have been devised to calculate the dose of carboplatin required to
achieve the desired target exposure or area under the plasma
concentration–time curve (AUC) (Calvert et al, 1989; Newell et al,
1993; Ando et al, 2000). This approach has been shown to result in
more consistent exposure to carboplatin than dosing based on
body surface area in a randomized, cross-over study in children
with cancer (Thomas et al, 2000). Renal function-based carbo-
platin dosing has now become widely accepted, with an increasing
number of paediatric clinical protocols specifying carboplatin
dosed to a target AUC. The rationale for this approach is
supported by the observation that carboplatin AUC is correlated
more closely than drug dose with both clinical toxicity and
response in adults and children (Newell et al, 1987; Jodrell et al,
1992).
Although this approach is now routinely used for carboplatin
administered at conventional doses (AUC 4–7mgml
 1.min), its
application to high-dose carboplatin chemotherapy is less well
understood. When high-dose chemotherapy is used in the
treatment of poor prognosis patients, saturation of protein binding
or drug metabolism may result in unpredictable pharmacokinetic
variation. Our group and others have previously suggested that
real-time carboplatin monitoring, involving dose modification
based on pharmacokinetic variation, can result in the achievement
of target exposures in individual patients following carboplatin
chemotherapy (Veal et al, 1999; Chatelut et al, 2000; Rubie et al,
2003). This approach to treatment may be particularly important
in a high-dose chemotherapy setting where treatment-related
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sdeaths are not uncommon. The current study, involving a
relatively large number of patients being treated with high-dose
carboplatin, was designed to determine whether adaptive dosing
would allow target AUC values to be consistently achieved, while
reducing the variability in plasma concentrations as compared to
renal function-based dosing.
In addition to learning more about the pharmacokinetics of
drugs used in the treatment of children with cancer, it is also
important to consider molecular pharmacodynamic interactions.
Although a number of studies have indicated relationships
between platinum–DNA adduct formation in peripheral blood
leucocytes and clinical response and toxicity following cisplatin
treatment, there is little evidence to support the use of
pharmacodynamic end points for carboplatin (Reed et al, 1990;
Schellens et al, 1996; Veal et al, 2001). Whether or not this can be
explained by a lack of correlation between carboplatin pharma-
cokinetics and pharmacodynamics is at present unclear.
The design of a United Kingdom Children’s Cancer Study Group
(UKCCSG) protocol for the treatment of low-risk patients with
metastatic rhabdomyosarcoma and other malignant soft tissue
sarcomas (MMT 98 study) provided a rare opportunity to
investigate carboplatin exposure, platinum–DNA adduct forma-
tion and clinical toxicity, in a single agent high-dose paediatric
setting. Additional data were also obtained from a UKCCSG study
involving the treatment of recurrent central nervous (CNS) system
primitive neuroectodermal tumours (Recurrent PNET study).
Carboplatin was administered with target AUCs of 20mgml
 1.min
over 5 days or 21mgml.min over 3 days for the treatment of soft
tissue sarcoma or recurrent PNET patients respectively. Carbo-
platin pharmacokinetics were monitored following initial renal
function-based dosing, with dose adjustments implemented based
on observed AUC values. In a subset of patients, platinum–DNA
adduct levels were determined in peripheral blood leucocytes.
PATIENTS AND METHODS
Patient eligibility and treatment
The study protocols were approved by the UK Northern and
Yorkshire Multicentre Research Ethics Committee and participa-
ting centres obtained local ethical approval; written informed
consent was required, either from patients or parents as
appropriate, for all patients entered onto the study. Patients, 21
years or younger, receiving high-dose carboplatin chemotherapy
as part of their standard clinical treatment, were eligible (Table 1).
Patients were being treated on clinical protocols for either soft
tissue sarcoma (UKCCSG MMT 98 study) or recurrent primitive
neuroectodermal tumour (UKCCSG recurrent PNET study). All
patients were required to have central venous access, in the form
of double-lumen central venous catheters, to participate in this
pharmacokinetic study.
Carboplatin was administered diluted in 5% dextrose, as a
60min intravenous infusion, as part of the standard chemotherapy
regimen that each patient was currently receiving. The dose of
carboplatin administered on day 1 of treatment was determined by
the renal function of the patient, based on either
51Cr-EDTA half-
life or glomerular filtration rate (GFR), using equations described
previously (Newell et al, 1993). Patients being treated for soft
tissue sarcoma received carboplatin dosed to a target AUC of
20mgml
 1.min over a 5-day treatment period. Before entering this
high-dose consolidation phase of chemotherapy, patients were
entered onto a phase II ‘window study’ consisting of single-agent
carboplatin targeted to obtain an AUC of 10mgml
 1.min on each
of the two courses of treatment. Patients being treated for
recurrent CNS primitive neuroectodermal tumours received
carboplatin dosed to a target AUC of 21mgml
 1.min over 3 days.
These dosages were determined by the clinical protocols for the
specific tumour types. Toxicity following carboplatin treatment
was assessed by the National Cancer Institute Common Toxicity
Criteria (CTC), version 2.0.
Blood sampling and analysis
Blood samples (2ml) for pharmacokinetic analysis were obtained
from a central line before carboplatin infusion, 30min after the
start of infusion, at 60min (end of infusion) and at 120min after
the start of infusion (60min post-infusion). All samples were taken
from a different lumen from that used for drug administration.
Plasma was separated from whole blood samples by centrifugation
(1200g, 41C, 10min), and 1ml was then removed and placed in an
Amicon Centrifree micropartition unit with a 30000 MW cutoff
(Millipore, Edinburgh, UK). This plasma sample was centrifuged
(1500g, 41C, 15min) to obtain plasma ultrafiltrate for determina-
tion of free carboplatin levels. Samples were sent by overnight
courier, on dry ice and in an insulated container, to the Northern
Institute for Cancer Research, Newcastle University, and were
stored at  201C before analysis.
Platinum pharmacokinetic analyses were carried out by flame-
less atomic absorption spectrophotometry (AAS) using a Perkin–
Elmer AAnalyst 600 graphite furnace spectrometer (Perkin-Elmer
Ltd, Beaconsfield, UK). Free or unbound platinum levels were
determined in plasma ultrafiltrates as described previously (Veal
et al, 2001). All samples were analysed in duplicate and values are
expressed as the average of these measurements. Duplicate values
were within 15% of each other in all cases. Intra- and interassay
coefficients of variation for a quality assurance sample had to be
o10% for an assay to be valid. The limit of detection for the AAS
assay was 0.10mgml
 1.
Pharmacokinetics and dose adjustment
Carboplatin clearance and AUC were determined by Bayesian
analysis following each dose of carboplatin using a two compart-
Table 1 Patient characteristics
Characteristic No. of patients %
Age, (years)
o54 1 4
5–9 5 18
10–14 12 43
15–21 7 25
Sex
Male 14 50
Female 14 50
Diagnosis
Soft tissue sarcoma (MMT 98) 5 18
Rhabdomyosarcoma (MMT 98) 12 43
PNET 11 39
Additional chemotherapy
Etoposide 17 61
Cyclophosphamide 28 100
Thiotepa 11 39
PNET, primitive neuroectodermal tumour. For patients treated on the MMT 98
study, cyclophosphamide (2gm
 2day
 1 3) was administered to patients on two
courses of treatment, 6 and 2 weeks before receiving high-dose carboplatin, with
etoposide (800mgm
 2day
 1 3) given 4 weeks before carboplatin. Patients
treated on the PNET study received both cyclophosphamide (2gm
 2day
 1 2)
and thiotepa (300mgm
 2day
 1) before high-dose carboplatin with time between
chemotherapy treatments dependent on neutrophil and platelet count recovery.
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sment model as described previously (Peng et al, 1995). For patients
being treated on a 5-day carboplatin schedule, dosing was adjusted
on days 2–5, based on drug exposures and clearance values
determined for day 1, or for days 1 and 2, to achieve the desired
target cumulative AUC of 20mgml
 1.min. For patients being
treated on the 3-day carboplatin schedule, dosing was adjusted
on day 3, based on drug exposure on day 1, to achieve the desired
target cumulative AUC of 21mgml
 1.min. Carboplatin dose
adjustments were recommended for all patients with day 1 AUC
values X10% outside the target daily AUC defined in the clinical
protocol on which the patient was being treated. Dose adjustments
were calculated based on the actual carboplatin clearance
determined on day 1 and the remaining AUC to be achieved.
Platinum–DNA adduct measurement
Whole blood samples were taken before the start of treatment, 24h
after the first dose of carboplatin on day 1 and 24h after the final
dose of carboplatin on day 5 for those patients being treated over a
5-day period. Cellular DNA was isolated from peripheral blood
leucocytes as described previously (Peng et al, 1995) and the
concentration of DNA in each sample was quantified by UV
absorption (A260). DNA samples were diluted in 3.5% nitric acid
and were hydrolysed overnight at 701C. Platinum–DNA adduct
levels were determined by ultrasensitive multi-collector inductively
coupled plasma mass spectrometry (ICP-MS) as described
previously (Cooper et al, 2004; Nowell et al, 2005). The limits of
detection and quantitation using this methodology were 0.3 and
1amol platinumml
 1 (1amol¼1 10
 18 molml
 1), respectively.
Final platinum–DNA adduct levels were calculated as nmolesg
 1
DNA and the results of duplicate analyses were within 10% of each
other in all cases.
Statistical analysis
Linear regression analysis and the Pearson correlation coefficient
were used to indicate correlations between patient GFR and %
target carboplatin AUC and between observed carboplatin AUC
and platinum–DNA adduct levels. The unpaired two-sided
Student’s t-test was used to determine differences between GFR
values in patients who would have experienced AUC values greater
than 25% above the target AUC and in patients who would have
experienced AUC values greater than 25% below the target AUC,
if no carboplatin dose modification had been carried out. The
paired Student’s t-test was used to determine differences between
carboplatin clearance values observed on day 1 vs day 3 and on day
1 vs day 5 of treatment. Log-transformed values of AUC, GFR and
clearance were used for all statistical tests described.
RESULTS
Patient characteristics and treatment
Children were treated at 12 UKCCSG centres for soft tissue
sarcoma or recurrent primitive neuroectodermal tumour. Twenty-
eight children and adolescents receiving carboplatin were entered
onto the two studies between September 1998 and November 2005.
The study population had a mean age of 11.7 years (range 1–21)
and included 14 men and 14 women. Renal function-based
carboplatin dosing was carried out on day 1 of treatment, with
the target exposure defined in the clinical protocol on which the
child was being treated. Patient characteristics including age, sex
and tumour type are given in Table 1.
Pharmacokinetics and dose adjustment
Carboplatin clearance values ranged from 25 to 195mlmin
 1 and
showed a good correlation with GFR values of 21–228mlmin
 1
(50–200mlmin
 11.73m
 2) determined before day 1 of treatment
(r¼0.73, Po 0.0001). No significant changes in clearance were
observed in those patients where clearance values were determined
on days 1 and 3 of carboplatin treatment (mean of differences:
9.6mlmin
 1; 95% CI  2.9 to 22.1; n¼17; P¼0.32) or on days 1
and 5 of treatment (mean of differences: 8.5mlmin
 1; 95% CI  4.3
to 21.3; n¼12; P¼0.16).
Pharmacokinetic monitoring was carried out in 28 patients
receiving high-dose carboplatin chemotherapy. Details of esti-
mated and actual total doses and carboplatin exposures are shown
for all patients in Table 2. On the basis of AUC values obtained
on day 1 following renal function-based dosing, and target daily
AUC values defined in the treatment protocol, carboplatin dose
adjustment was carried out in 21 out of 28 patients (75%). Dosage
adjustments from the day 1 dose were carried out on day 2 of
treatment in one patient, day 3 in 12 patients, day 4 in six patients,
with two different adjustments carried out on both days 3 and 5
in the remaining two patients. Dosage adjustments in these 21
patients ranged from 7 to 67% of the initial renal function-based
dose. For those patients where carboplatin dose was modified,
dose increases were implemented in 43% of patients (9/21) and
dose reductions in 57% (12/21). Examples of carboplatin dosing
and exposure in individual patients requiring dosage adjustments
based on drug exposure data are shown in Figure 1. Overall,
pharmacokinetically guided dose adjustment resulted in achieve-
ment of AUC values of 16.7–25.2mgml
 1.min (84–126% of target
AUC values) as compared to estimated AUC values of 13.0–
44.7mgml
 1.min (65–213% of target AUC values) without dose
adjustment (Figure 2). Estimated AUC values were calculated
based on the observed daily carboplatin clearance values,
assuming that the day 1 renal function-based dose had been
administered on each day of treatment, as opposed to the adjusted
dose actually administered.
The relationship between the renal function of patients receiving
high-dose carboplatin treatment and the predicted AUC that would
have been obtained if no dose modification had been carried out
is shown in Figure 3 (r¼0.54; P¼0.003). Pretreatment GFR
values were higher in those patients who would have experienced
AUC values greater than 25% above the target AUC (mean
value 121mlmin
 1, range 94–158; standardized mean value
137mlmin
 11.73m
 2, range 81–200; n¼8) than those who
would have experienced AUC values 425% below the target
AUC (mean value 57mlmin
 1, range 32–101; standardized mean
value 81mlmin
 11.73m
 2, range 50–111; n¼5) (P¼0.0139).
Platinum–DNA adduct measurements
Carboplatin–DNA adduct levels were measured in DNA samples
isolated from peripheral blood leucocytes from 8 of the 17 patients
on the MMT 98 study on a total of 12 courses of carboplatin
administration. Samples were obtained following carboplatin
dosed to a target AUC of 4mgml
 1.min on day 1 of a 5-day
course of treatment in six patients (carboplatin dose range: 380–
957mg), following carboplatin on day 5 of treatment in four of
these patients (carboplatin dose range: 203–860mg) and following
a single dose of carboplatin targeted to an AUC of 10mgml
 1.min
as part of a phase II window study in a total of three patients
(carboplatin dose range: 1140–1550mg). Platinum–DNA adduct
levels determined 24h post-administration on day 1 of treatment
ranged from 0.24 to 2.29nmolesg
 1 DNA and correlated with the
observed carboplatin AUC values as shown in Figure 4 (r¼0.84,
P¼0.0006 for all data points shown; r¼0.81, P¼0.01 when the
analysis is limited to a single data point for each individual
patient). Additional measurements determined 24h post-adminis-
tration on day 5 of treatment were obtained for four patients
and indicated a clear increase in platinum–DNA adduct levels as
compared to the corresponding day 1 levels (P¼0.01), suggesting
an increased level of adduct formation or an accumulation of
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sadducts over the 5-day treatment period (Table 3). Overall,
platinum–DNA adduct levels ranged from 0.24 to 6.99nmoleg
 1
DNA, with corresponding peak unbound carboplatin plasma
concentrations ranging from 15.8 to 76.6mgml
 1. These levels
are well above the limits of detection and quantitation of the ICP-
MS technique used (16). No correlations were observed between
platinum–DNA adduct formation and other parameters investi-
gated, such as body weight, age or gender of patients studied.
Carboplatin toxicity
Toxicity data were available for a total of 23 of the 28 patients
studied, including 14 patients treated on the MMT 98 study and
nine patients on the PNET study. Haematological toxicity (CTC
grade 3 or 4), including neutropenia and thrombocytopenia,
was observed in 91% (21/23) of patients overall. This level of
haematological toxicity was reported in 86% of MMT 98 patients
(12/14), who received carboplatin targeted to an AUC of
20mgml
 1.min over a 5-day treatment period, and in 100% of
patients (9/9), who received high-dose carboplatin targeted to an
AUC of 21mgml
 1.min over the shorter 3 day regimen on the
PNET study. No treatment-related deaths were observed in any of
the 28 patients studied.
DISCUSSION
The current study was carried out to investigate the variation in
carboplatin pharmacokinetics and exposure and to determine the
potential importance of therapeutic monitoring following high-
dose carboplatin treatment in children. In addition, platinum–
DNA adduct levels were measured in peripheral blood leucocytes,
to allow a comparison of carboplatin pharmacodynamics and
pharmacokinetics alongside clinical toxicity data. Clinical response
data were not evaluated due to the potential role played by
concomitant chemotherapy, administered either before or follow-
ing high-dose carboplatin treatment, on the tumour responses
observed.
A total of 28 patients were included in the study with the dose of
carboplatin on day 1 based on renal function to achieve a target
AUC. No significant interoccasion variability in carboplatin
clearance was observed in those patients where clearance values
were determined on the first and last days of treatment, although
mean clearance values were lower on days 3 and 5 vs comparable
day 1 data. Interestingly, these data are in agreement with those
published from a phase I study, which reported a statistically
significant, but limited, decrease in clearance between days 1 and 5
of high-dose carboplatin treatment (Rubie et al, 2003).
On the basis of the observed AUC values in individual patients,
carboplatin dose adjustment was carried out in 75% of patients,
with a range of dose adjustments up to a maximum of 67% from
the initial estimated dose. These dose changes resulted in drug
exposures of 84–126% of the target AUC values as defined in the
two study protocols. In comparison, estimated carboplatin
exposures of 65–213% of the target AUC values would have been
attained without dose adjustment, with 32% of patients (9/28)
receiving carboplatin AUC values above 25mgml
 1.min. The
likelihood of dose adjustment was not influenced by the method of
Table 2 Carboplatin doses and estimated renal function-based dosing AUC vs actual AUC following pharmacologically guided dosing
Estimated Achieved
Study Patient
GFR
(mlmin
 1)
Target AUC
(mgml
 1.min)
Dose
modification
Estimated total
dose (mg)
a
Actual total
dose (mg)
AUC
b
(mgml
 1.min)
% target
AUC
AUC
(mgml
 1.min)
% Target
AUC
MMT 98 1 110 20 Day 3 2610 1653 30.3 152 19.6 98
2 115 20 Day 3 2720 2921 18.7 94 ND ND
3 104 20 Day 3 2350 1450 32.0 160 19.8 99
4 158 20 Day 2 3660 2868 32.6 163 25.2 126
5 85 20 None 2090 2090 20.7 104 20.7 104
6 71 20 None 1750 1750 21.5 108 ND ND
7 73 20 Day 4 1900 2860 15.4 77 23.7 119
8 90 20 Day 4 1565 1243 23.8 119 19.0 95
9 21 20 Day 3 575 508 22.5 113 ND ND
10 228 20 Day 3 4785 4071 23.5 118 ND ND
11 30 20 Day 3 750 970 16.9 85 22.1 111
12 56 20 Days 3/5 1350 1790 14.8 74 19.3 97
13 59 20 Days 3/5 1475 1575 17.9 90 19.5 98
14 62 20 Day 4 1500 2500 13.0 65 22.6 113
15 97 20 Day 4 2160 2696 15.0 75 18.8 94
16 101 20 Day 4 2650 4070 13.0 65 ND ND
17 145 20 Day 4 3400 2664 26.5 133 20.1 101
PNET 18 34 21 None 1026 1026 15.3 73 ND ND
19 104 21 Day 3 3720 2830 27.6 131 ND ND
20 74 21 None 1590 1590 16.7 80 16.7 80
21 97 21 Day 3 3141 2554 25.8 123 ND ND
22 124 21 Day 3 3258 2387 30.7 146 20.7 99
23 32 21 Day 3 900 1130 14.5 69 19.0 90
24 128 21 Day 3 4320 2880 44.7 213 ND ND
25 74 21 None 1608 1608 21.0 100 21.0 100
26 42 21 None 1020 1020 20.1 96 20.1 96
27 94 21 Day 3 3000 2360 26.7 127 ND ND
28 40 21 None 870 870 20.2 96 20.2 96
Range: MMT 98 13.0–32.6 65–163 18.8–25.2 94–126
PNET 14.5–44.7 69-213 16.7–21.0 80–100
aEstimated total dose is based on the day 1 renal function-based dose without modification.
bEstimated total AUC is that which would have resulted if no dose adjustment had
been made (based on daily carboplatin clearance values)
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sGFR determination or the dosing equation used to determine
initial renal function-based dosing. Based on previous studies
showing correlations between carboplatin AUC and drug toxicity
following high-dose chemotherapy, it is likely that patients with an
AUC greater than 25mgml
 1.min would have experienced serious
side effects if therapeutic monitoring had not been implemented
(Huitema et al, 2002; Kloft et al, 2002). Indeed, significantly
increased frequencies of nephrotoxicity, ototoxicity and peripheral
nervous system toxicities were observed in patients with AUC
above 24.2mgml
 1.min in a recently published study in patients
with germ-cell cancer (Kloft et al, 2003).
In the current study, a positive correlation was observed
between renal function (GFR) and the estimated AUC that would
have been observed if pharmacologically guided dosing had not
been performed. Pretreatment GFR values were significantly
higher in those patients whose AUC values would have exceeded
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Figure 1 Examples of carboplatin pharmacokinetically guided dosing and
exposure (AUC) in individual patients showing (A) a dose reduction
implemented on day 3 to achieve a cumulative AUC of 19.6mgml
 1.min
over 5 days of treatment and (B) dose increases on days 3 and 5 resulting
in a cumulative AUC of 19.3mgml
 1.min.
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Figure 2 Predicted vs actual carboplatin exposures following pharma-
cokinetically guided dosage adjustment in children receiving high-dose
carboplatin chemotherapy (n¼28).
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Figure 4 Correlation between actual carboplatin exposure (AUC) and
platinum–DNA adduct levels measured in peripheral blood leucocytes
obtained 24h after high-dose carboplatin administration on day 1 of a
course of treatment. Data represents samples analysed from six patients
receiving carboplatin on day 1 of high-dose carboplatin treatment (MMT 98
study) and three patients receiving carboplatin on day 1 of each of two
courses of a high-dose carboplatin window study (MMT 98).
Table 3 Platinum–DNA adduct levels determined in patients following
carboplatin administration on days 1 and 5 of treatment in four patients on
the MMT 98 protocol
Patient
Study
day
Carboplatin
dose (mg)
Carboplatin AUC
(mgml
 1.min)
Pt-DNA adducts
(nmolg
 1DNA)
1 1 522 5.2 2.28
5 203 1.9 6.99
2 1 380 2.5 0.24
5 860 7.8 2.21
3 1 732 5.1 0.59
5 534 5.8 4.06
4 1 418 3.8 0.57
5 418 4.2 3.21
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sthe target by 25% without dose modification (n¼8), than in those
whose AUC values would have been more than 25% below the
target AUC (n¼5). There was a greater than twofold difference in
mean GFR between these two groups (P¼0.0139). These data
suggest that the current use of dosing equations is less effective
when dealing with patients receiving high-dose carboplatin
chemotherapy, with children with higher GFR values being more
likely to attain AUC values greater than intended, and those with
lower GFR values being at a greater risk of under-exposure.
Platinum–DNA adducts were measured at 24h after carboplatin
administration, as this has previously been shown to be the time
when peak adduct levels are observed following platinum drug
treatment (Peng et al, 1997). In addition, this allowed the blood
sample to be drawn immediately before the next dose of
carboplatin being administered in those patients receiving the
drug over several days. A strong correlation was observed between
the formation of platinum–DNA adducts and carboplatin AUC on
day 1 of treatment, with higher adduct levels being observed in
peripheral blood leucocytes obtained from patients with higher
plasma carboplatin concentrations. Pharmacokinetic–pharmaco-
dynamic comparisons with the platinum drugs have not always
shown a consistent positive relationship (Schellens et al, 1996;
Peng et al, 1997; Veal et al, 2001). However, carboplatin seems to
show a stronger trend towards such a relationship than does
cisplatin (Ghazal-Aswad et al, 1999). The correlation between this
pharmacodynamic measure and drug exposure supports the use
of dosing based on renal function and adaptive dosing to achieve
target carboplatin AUC values. Similarly, the lack of a pharmaco-
kinetic–pharmacodynamic relationship for cisplatin may explain
why such an approach to dosing has not been established for this
drug.
The current study also suggests that when carboplatin is
administered over several days, there is either an increased
formation of platinum–DNA adducts or an accumulation of
adducts over the treatment period. Despite the complication of
carboplatin dose variations between days 1 and 5 of treatment,
owing to pharmacokinetic dose adjustment, adduct levels follow-
ing carboplatin administration on day 5 were between 3- and
10-fold higher than the corresponding levels following day 1 of the
treatment. This phenomenon may explain some of the apparent
inconsistencies in published pharmacokinetic–pharmacodynamic
relationships for this drug. For example, although a strong
correlation was observed between platinum–DNA adduct levels
and carboplatin systemic exposure following administration on
day 1 in the current study, the accumulation of adduct levels
observed following several days of treatment negated this relation-
ship when data from all days of treatment were included in a
similar analysis. Although we are unable to determine cumulative
platinum–DNA adduct levels over the 5-day treatment period,
with no information on adduct levels on days 2–4, it is possible
that differences in total adduct levels may reflect differences in
observed toxicity among some patients, despite comparable
cumulative pharmacokinetic exposures in terms of AUC. Indeed,
correlations have previously been shown between platinum–DNA
adduct levels and leukocytopenia following cisplatin treatment
(Veal et al, 2001).
Haematological toxicity was observed in the vast majority of
patients studied (90%), as anticipated with the use of high-dose
carboplatin chemotherapy. The high percentage of patients
experiencing CTC grade 3 and 4 haematological toxicity is likely
to be associated with the high carboplatin exposures achieved in all
patients through adaptive dosing. Estimated exposures as low as
13.0mgml
 1.min, which would have been achieved in some of the
patients studied if dose adjustment had not been carried out, may
not have led to the same grade toxicity but may also have been less
likely to have resulted in clinical responses. Correlations between
decreased carboplatin AUC values and increased rates of relapse
have previously been reported in patients with testicular germ-cell
tumours (Horwich et al, 1991). Although an evaluation of clinical
response data was not included in this study, owing to the
potential influence of concomitant chemotherapy, it is encoura-
ging that no treatment-related deaths were observed in any of the
patients on the current study. This is particularly the case in light
of the high incidence of treatment-related deaths previously
reported with the use of high-dose carboplatin in paediatric
patients (Santana et al, 1992; Jakacki et al, 1997; Dunkel et al,
1998).
Data from this multi-centre study show the feasibility of
real-time monitoring of carboplatin pharmacokinetics with
adaptive dosing and indicate that this approach is necessary
for the attainment of consistent AUC values in individual
patients receiving high-dose carboplatin treatment. This approach
is now being used in clinical studies in the UK, with the aim of
improving efficacy and minimising toxicity of carboplatin in
similar high-dose protocols, and is likely to be relevant to the
treatment of both childhood and adult cancer patients. The
pharmacodynamic data presented here suggest that a strong
correlation exists between the pharmacokinetics of carboplatin
and the drug–target interaction.
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